An interventional study of transcranial direct current stimulation (tDCS) in Alzheimer's Disease and Frontotemporal Dementia, Behavioral Variant, sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli. Completed at 1 site in Italy. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Alzheimer Disease with a site in Italy — 54 open to participants now, 73 under way, 19 of them phase 3. Alzheimer Disease · Italy.
Among the 206 studies in Alzheimer Disease with a site in Italy, this one is the 152nd largest by enrollment of the 170 interventional ones that give a count, is one of 8 that started in 2015, is one of 54 with no phase, and was the 82nd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →54 of the 206 studies in Alzheimer Disease with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 18+
University of Siena · Sites in Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 55–80 · Healthy volunteers
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Italy, Australia, Austria and 14 more countries
Ages 18+
Casa di Cura Dott. Pederzoli · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 47 · Phase 3 75 · Phase 4 2
First in 2003; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 328 across the 170 interventional studies, 273 across the 36 observational. Of the 124 that completed or were terminated, 64 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 206 have an industry lead sponsor. The 10 most frequent:
IRCCS Centro San Giovanni di Dio Fatebenefratelli is the lead sponsor of 36 studies on the registry; 15 are open to participants now.
IRCCS Centro San Giovanni di Dio Fatebenefratelli has 6 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Alzheimer Disease with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06179680IRCCS Policlinico S. DonatoWhite Matter Hyperintensities in Amnestic Mild Cognitive Impairment or Alzheimer's Disease | 2026-12 |
| NCT07431255IRCCS San RaffaeleGeneration of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 206 studies in Alzheimer Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study aims to test clinical and connectivity changes following non-invasive stimulation of disease-specific networks in Alzheimer's disease (AD) and behavioral variant frontotemporal dementia (bvFTD). Brain network stimulation will be carried out with transcranial direct current stimulation (tDCS). Target networks will be the default mode network (DMN) and salience network (SN). Twenty AD and 20 bvFTD patients will be recruited and assessed with a comprehensive clinical, behavioral and cognitive battery, and 3 Tesla MRI scan (including resting-state functional MRI, arterial spin labeling, diffusion tensor imaging, structural MRI) at three time-points: baseline, after tDCS, and after 6 months. Patients will be randomized to 2 arms: anodal stimulation of the disease-specific network (DMN in AD, SN in bvFTD) or cathodal stimulation of the anti-correlated network (SN in AD, DMN in bvFTD). The intervention will consist of 10 tDCS sessions over two weeks. Cerebrospinal fluid (CSF) samples will be collected at baseline for biomarker's assessment; blood samples will be collected at each time-point to assess changes in peripheral inflammatory markers. Blood and CSF collection will be optional. A sample of 20 elderly controls will be included for baseline comparisons.
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria for MRI and tDCS:
Exclusion Criteria for controls:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alzheimer's disease (AD): anodal tDCS of the default mode network (DMN)
Device: transcranial direct current stimulation (tDCS)
Alzheimer's disease (AD): cathodal tDCS of the salience network (SN)
Device: transcranial direct current stimulation (tDCS)
Behavioral-variant frontotemporal dementia (bvFTD): anodal tDCS of the salience network (SN)
Device: transcranial direct current stimulation (tDCS)
Behavioral-variant frontotemporal dementia (bvFTD): cathodal tDCS of the default mode network (DMN)
Device: transcranial direct current stimulation (tDCS)
10 daily 25-minutes tDCS sessions over two weeks.
Change in Clinical Disease Severity (CDR)
CDR - Clinical Dementia Rating score The clinical dementia rating (CDR) is a clinical global rating scale administered to both the participant and the caregiver, assessing 6 domains of participant function: memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care. Each domain is based on a 5-point scale ranging from no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 to severe impairment=3. The global CDR score is computed via a memory-weighted averaging algorithm of the six domain scores and ranges from 0 to 5. The CDR-sum of boxes (CDR-SB) is the sum of the individual domain scores and ranges from 0 to 18. Higher scores indicate more clinical impairment. Negative changes at post tDCS compared to baseline represent an improvement on the scale.
Time frame: Baseline, post tDCS (week 3)
Change in Behavioral Symptom Severity (NPI)
The Neuropsychiatric Inventory (NPI) is a behavioral scale administered to the caregiver assessing 12 dimensions: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor activity, nighttime behaviors, and appetite/eating. Each dimension has multiple screening questions relating to symptoms. If the answer to the screening questions is "Yes", the dimensional-score is the product of frequency (1=occasionally to 4=very frequently) and severity (1=Mild to 3=Severe) of symptoms. Dimensional-scores are summed (from 0 to 144). Higher scores indicate greater behavioral disturbances. Negative changes at post tDCS compared to baseline represent an improvement on the scale.
Time frame: Baseline, post tDCS (week 3)
Change in Behavioral Symptom Severity (FBI)
The Frontal Behavioral Inventory (FBI) is a 24-item inventory designed to assess behavior and personality changes via caregiver. Item-level scores range from 0=none, 1=mild/occasional, 2=moderate, 3=severe/most of the time. Item-scores are summed (from 0 to 72). Higher scores indicate greater behavioral/personality disturbances. Negative changes at post tDCS compared to baseline represent an improvement on the scale.
Time frame: Baseline, post tDCS (week 3)
Change in Functional Connectivity
Default mode network (DMN) and salience network (SN) mean functional connectivity is assessed on resting state functional MRI. Functional connectivity is standardized to Z scores and thresholded at Z\>2. Higher values denote greater functional connectivity. A positive change at post tDCS compared to baseline represents an increase in resting-state functional connectivity.
Time frame: Baseline, post tDCS (week 3)
Change in Cerebral Blood Flow
Default mode network (DMN) and salience network (SN) mean cerebral blood flow is assessed on arterial spin labeling. Cerebral blood flow is computed by averaging values across the DMN and SN regions of interest. Cerebral blood flow is a measure of brain perfusion, higher values denoting higher perfusion. A positive change at post tDCS compared to baseline represents an increase in perfusion.
Time frame: Baseline, post tDCS (week 3)
Change in Cognition: Memory
The composite memory score consists of the averaged Z-standardized scores of 5 memory tests: immediate and delayed auditory verbal learning test recall, Rey-Osterrieth complex figure recall, story recall, digit span backward and forward tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better memory performance. Positive changes at post tDCS compared to baseline represent an improvement in memory.
Time frame: Baseline, post tDCS (week 3)
Change in Cognition: Language
The composite language score consists of the averaged Z-standardized scores of 2 language tests: verbal fluency and token tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better language performance. Positive changes at post tDCS compared to baseline represent an improvement in language.
Time frame: Baseline, post tDCS (week 3)
Change in Cognition: Executive Function
The composite executive function score consists of the averaged Z-standardized scores of 2 executive functions tests: trail making test part A and part B tests. Each test score is normalized to an independent dataset of healthy controls and inverted. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better executive function performance. Positive changes at post tDCS compared to baseline represent an improvement in executive functions.
Time frame: Baseline, post tDCS (week 3)
Change in Cognition: Visuospatial Function
The visuospatial function score consists of the Z-standardized scores for the Rey-Osterrieth complex figure copy test. Scores are normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better visuospatial performance. Positive changes at post tDCS compared to baseline represent an improvement in visuospatial functions.
Time frame: Baseline, post tDCS (week 3)
Change in Cognition: Emotion Recognition
The composite emotion recognition score consists of the averaged Z-standardized scores for 2 emotion recognition tests: reading the Mind in the Eyes and 60 Ekman faces tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better emotion recognition performance. Positive changes at post tDCS compared to baseline represent an improvement in emotion recognition.
Time frame: Baseline, post tDCS (week 3)
Change in Structural Connectivity: FA
Fractional anisotropy (FA) is assessed on diffusion weighted imaging. FA values are averaged in default mode network (DMN) and salience network (SN) regions of interest. FA values denote the directionality of water diffusivity, ranging from 0 (isotropic diffusion) to 1 (anisotropic diffusion). Higher values denote higher directionality and connectivity. Positive changes at post tDCS compared to baseline represent an improvement in the measure.
Time frame: Baseline, post tDCS (week 3)
Change in Structural Connectivity: MD, AxD, RaD
Mean diffusivity (MD), axial diffusivity (AxD), and radial diffusivity (RaD) are assessed on diffusion weighted imaging. MD, AxD, RaD values are averaged in default mode network (DMN) and salience network (SN) regions of interest. MD, AxD, and RaD measure water diffusion and are expressed in mm\^2/s (starting from 0 with no maximum value; scaled at x10\^-3). Higher values denote higher diffusion and lower connectivity. Negative changes at post tDCS compared to baseline represent an improvement in the measure.
Time frame: Baseline, post tDCS (week 3)
| Milestone | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| Started | 11 | 11 | 12 | 11 |
| Completed | 10 | 10 | 10 | 10 |
| Not completed | 1 | 1 | 2 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 |
| Withdrew: Safety (psoriasis, cortical vascular lesions on mri) | 1 | 0 | 2 | 0 |
| Milestone | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 |
| Completed | 10 | 10 | 10 | 8 |
| Not completed | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
CDR - Clinical Dementia Rating score The clinical dementia rating (CDR) is a clinical global rating scale administered to both the participant and the caregiver, assessing 6 domains of participant function: memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care. Each domain is based on a 5-point scale ranging from no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 to severe impairment=3. The global CDR score is computed via a memory-weighted averaging algorithm of the six domain scores and ranges from 0 to 5. The CDR-sum of boxes (CDR-SB) is the sum of the individual domain scores and ranges from 0 to 18. Higher scores indicate more clinical impairment. Negative changes at post tDCS compared to baseline represent an improvement on the scale.
| score on a scale | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| CDR global | -0.1 ± 0.2 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| CDR sum of boxes | 0.1 ± 0.4 | 0.0 ± 0.2 | -0.1 ± 0.3 | 0.0 ± 0.0 |
The Neuropsychiatric Inventory (NPI) is a behavioral scale administered to the caregiver assessing 12 dimensions: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor activity, nighttime behaviors, and appetite/eating. Each dimension has multiple screening questions relating to symptoms. If the answer to the screening questions is "Yes", the dimensional-score is the product of frequency (1=occasionally to 4=very frequently) and severity (1=Mild to 3=Severe) of symptoms. Dimensional-scores are summed (from 0 to 144). Higher scores indicate greater behavioral disturbances. Negative changes at post tDCS compared to baseline represent an improvement on the scale.
| score on a scale | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| Change in Behavioral Symptom Severity (NPI) | -1 ± 3 | -3 ± 6 | -1 ± 4 | -6 ± 11 |
The Frontal Behavioral Inventory (FBI) is a 24-item inventory designed to assess behavior and personality changes via caregiver. Item-level scores range from 0=none, 1=mild/occasional, 2=moderate, 3=severe/most of the time. Item-scores are summed (from 0 to 72). Higher scores indicate greater behavioral/personality disturbances. Negative changes at post tDCS compared to baseline represent an improvement on the scale.
| score on a scale | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|
| Change in Behavioral Symptom Severity (FBI) | -2 ± 4 | -4 ± 8 |
Default mode network (DMN) and salience network (SN) mean functional connectivity is assessed on resting state functional MRI. Functional connectivity is standardized to Z scores and thresholded at Z\>2. Higher values denote greater functional connectivity. A positive change at post tDCS compared to baseline represents an increase in resting-state functional connectivity.
| Z-score | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| DMN | 0.08 ± 0.13 | -0.09 ± 0.11 | -0.02 ± 0.23 | -0.04 ± 0.15 |
| SN | -0.06 ± 0.15 | 0.05 ± 0.2 | 0.08 ± 0.18 | 0.02 ± 0.12 |
Default mode network (DMN) and salience network (SN) mean cerebral blood flow is assessed on arterial spin labeling. Cerebral blood flow is computed by averaging values across the DMN and SN regions of interest. Cerebral blood flow is a measure of brain perfusion, higher values denoting higher perfusion. A positive change at post tDCS compared to baseline represents an increase in perfusion.
| ml/100g/min | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| DMN | 4.87 ± 8.92 | -0.06 ± 9.46 | 0.56 ± 7.72 | 3.08 ± 3.45 |
| SN | 4.37 ± 7.00 | -1.92 ± 12.3 | 2.34 ± 4.84 | 1.41 ± 4.09 |
The composite memory score consists of the averaged Z-standardized scores of 5 memory tests: immediate and delayed auditory verbal learning test recall, Rey-Osterrieth complex figure recall, story recall, digit span backward and forward tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better memory performance. Positive changes at post tDCS compared to baseline represent an improvement in memory.
| z score | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| Change in Cognition: Memory | 0.3 ± 0.2 | 0.3 ± 0.3 | 0.1 ± 0.3 | 0.2 ± 0.3 |
The composite language score consists of the averaged Z-standardized scores of 2 language tests: verbal fluency and token tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better language performance. Positive changes at post tDCS compared to baseline represent an improvement in language.
| z score | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| Change in Cognition: Language | 0.7 ± 0.6 | 0.4 ± 0.6 | 0.7 ± 0.9 | 0.4 ± 0.6 |
The composite executive function score consists of the averaged Z-standardized scores of 2 executive functions tests: trail making test part A and part B tests. Each test score is normalized to an independent dataset of healthy controls and inverted. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better executive function performance. Positive changes at post tDCS compared to baseline represent an improvement in executive functions.
| z score | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| Change in Cognition: Executive Function | 0.3 ± 2.9 | -0.3 ± 2.4 | 0.7 ± 2.3 | -0.7 ± 1.6 |
The visuospatial function score consists of the Z-standardized scores for the Rey-Osterrieth complex figure copy test. Scores are normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better visuospatial performance. Positive changes at post tDCS compared to baseline represent an improvement in visuospatial functions.
| z score | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| Change in Cognition: Visuospatial Function | 1.2 ± 1.1 | 0.0 ± 1.6 | 0.1 ± 0.8 | 0.4 ± 0.9 |
The composite emotion recognition score consists of the averaged Z-standardized scores for 2 emotion recognition tests: reading the Mind in the Eyes and 60 Ekman faces tests. Each test score is normalized to an independent dataset of healthy controls. Z-scores have no minimum/maximum values. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Higher values denote better emotion recognition performance. Positive changes at post tDCS compared to baseline represent an improvement in emotion recognition.
| z score | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| Change in Cognition: Emotion Recognition | 0.1 ± 0.5 | 0.1 ± 0.6 | 0.3 ± 1.2 | 0.1 ± 0.9 |
Fractional anisotropy (FA) is assessed on diffusion weighted imaging. FA values are averaged in default mode network (DMN) and salience network (SN) regions of interest. FA values denote the directionality of water diffusivity, ranging from 0 (isotropic diffusion) to 1 (anisotropic diffusion). Higher values denote higher directionality and connectivity. Positive changes at post tDCS compared to baseline represent an improvement in the measure.
| score on a scale | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| DMN FA | 0.000 ± 0.007 | -0.003 ± 0.006 | -0.002 ± 0.008 | 0.000 ± 0.008 |
| SN FA | 0.003 ± 0.009 | -0.002 ± 0.011 | -0.002 ± 0.009 | 0.001 ± 0.011 |
Mean diffusivity (MD), axial diffusivity (AxD), and radial diffusivity (RaD) are assessed on diffusion weighted imaging. MD, AxD, RaD values are averaged in default mode network (DMN) and salience network (SN) regions of interest. MD, AxD, and RaD measure water diffusion and are expressed in mm\^2/s (starting from 0 with no maximum value; scaled at x10\^-3). Higher values denote higher diffusion and lower connectivity. Negative changes at post tDCS compared to baseline represent an improvement in the measure.
| x10^-3 mm^2/s | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| DMN MD | -0.003 ± 0.017 | -0.001 ± 0.019 | 0.007 ± 0.008 | 0.007 ± 0.008 |
| SN MD | -0.004 ± 0.016 | -0.002 ± 0.017 | 0.010 ± 0.009 | 0.007 ± 0.008 |
| DMN AxD | -0.004 ± 0.017 | -0.006 ± 0.024 | 0.009 ± 0.014 | 0.008 ± 0.011 |
| SN AxD | -0.004 ± 0.017 | -0.008 ± 0.029 | 0.014 ± 0.018 | 0.010 ± 0.012 |
| DMN RaD | -0.002 ± 0.017 | 0.001 ± 0.017 | 0.007 ± 0.009 | 0.006 ± 0.009 |
| SN RaD | -0.005 ± 0.017 | 0.000 ± 0.015 | 0.008 ± 0.009 | 0.005 ± 0.011 |
Collected over Adverse events were monitored from the time of enrollment to follow-up assessment (approx 6 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AD: Anodal tDCS of the DMN | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| AD: Cathodal tDCS of the SN | 0/11 (0%) | 0/11 (0%) | 6/11 (54.5%) |
| bvFTD: Anodal tDCS of the SN | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| bvFTD: Cathodal tDCS of the DMN | 0/11 (0%) | 1/11 (9.1%) | 5/11 (45.5%) |
| Event | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| Intestinal infarctGastrointestinal disorders | 0/11 | 0/11 | 0/12 | 1/11 |
| Event | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN |
|---|---|---|---|---|
| Pinching (tDCS related discomfort sensation)Skin and subcutaneous tissue disorders | 5/11 | 5/11 | 3/12 | 1/11 |
| Itching (tDCS related discomfort sensation)Skin and subcutaneous tissue disorders | 0/11 | 3/11 | 1/12 | 1/11 |
| FatigueGeneral disorders | 2/11 | 1/11 | 0/12 | 0/11 |
| Burning (tDCS related discomfort sensation)Skin and subcutaneous tissue disorders | 2/11 | 1/11 | 0/12 | 2/11 |
| Chest painGeneral disorders | 0/11 | 1/11 | 0/12 | 0/11 |
| DizzinessNervous system disorders | 0/11 | 1/11 | 0/12 | 1/11 |
| HeadacheNervous system disorders | 0/11 | 0/11 | 0/12 | 1/11 |
| FallInjury, poisoning and procedural complications | 0/11 | 0/11 | 0/12 | 1/11 |
| Pain (tDCS related discomfort sensation)Skin and subcutaneous tissue disorders | 1/11 | 0/11 | 0/12 | 0/11 |
| Warmth/Heat (tDCS related discomfort sensation)Skin and subcutaneous tissue disorders | 0/11 | 1/11 | 0/12 | 0/11 |
Modified intention-to-treat sample (participants completing intervention)
| Age, Continuous(years) | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN | Total |
|---|---|---|---|---|---|
| Mean | 72 ± 6 | 73 ± 6 | 71 ± 10 | 69 ± 11 | 71 ± 8 |
| Sex/Gender, Customized(Participants) | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN | Total |
|---|---|---|---|---|---|
| Female | 6 | 4 | 3 | 5 | 18 |
| Male | 4 | 6 | 7 | 5 | 22 |
| Race (NIH/OMB)(Participants) | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 10 | 10 | 10 | 10 | 40 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | AD: Anodal tDCS of the DMN | AD: Cathodal tDCS of the SN | bvFTD: Anodal tDCS of the SN | bvFTD: Cathodal tDCS of the DMN | Total |
|---|---|---|---|---|---|
| Italy | 10 | 10 | 10 | 10 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2015 to primary completion in Nov 2018, 40 months.
Results were first posted in Apr 2021, 2 years 5 months after primary completion.
Of 886 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 40 months is above that.
Counting every sponsor, half of 963 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Centro San Giovanni di Dio Fatebenefratelli